Breaking Stories

Relmada’s stock tumbles 80% after its depressive disorder drug failed a late-stage study

Shares of Relmada Therapeutics Inc.
RLMD,
-0.97%

fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not meet the primary endpoint in a Phase 3 clinical trial. The company said it is still enrolling patients in two other late-stage studies assessing the therapy as an adjunctive treatment. Relmada’s stock is up 40.6% this year, while the broader S&P 500
SPX,
-0.33%

is down 24.7%.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *